Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates
Authors' conclusion
GLP1 agonists favorable initial effect on HbA1c and weight may not be sustainable beyond a certain period. The exact reason and factors contributing to this need further exploration.
Study context
- Population
- Patients with T2D at the Dubai Diabetes Center, United Arab Emirates
- Exposure
- Three GLP-1 RA
- Outcome
- Change in HbA1c and weight, and sustainability of change
- Follow-up
- 3, 6, 9 and 12 months
Methodological detailssingle-centre
- Single-centre
Main finding
As reported in the abstract
over one year
- Significant reduction in HbA1c and weight in the first 3 months, not clinically significant
- Change not maintained at end of year; effect diminishes by final quarter with partial weight regain
Observational data: associations, not effects.
Original publication
Institutional experience on the impact of glucagon-like peptide-1 agonists (GLP-1) on glycemic control and weight loss in patients with type 2 diabetes at the Dubai Diabetes Center, United Arab Emirates. Diabetes Res Clin Pract. Published 7 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →